ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) announced a quarterly dividend on Tuesday, September 22nd. Stockholders of record on Wednesday, September 23rd will be given a dividend of 0.0826 per share by the exchange traded fund on Tuesday, September 29th. This represents a c) dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Wednesday, September 23rd.
ProShares Ultra Nasdaq Biotechnology Stock Performance
NASDAQ:BIB traded down $5.12 on Wednesday, hitting $112.04. 10,286 shares of the stock were exchanged, compared to its average volume of 11,103. The stock has a market capitalization of $94.11 million, a price-to-earnings ratio of 20.68 and a beta of 1.22. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $55.34 and a 52 week high of $126.40. The company’s 50-day moving average price is $109.66 and its 200 day moving average price is $93.93.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in ProShares Ultra Nasdaq Biotechnology stock. Kaizen Financial Strategies increased its holdings in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) by 4.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,565 shares of the exchange traded fund’s stock after purchasing an additional 250 shares during the quarter. Kaizen Financial Strategies owned approximately 0.60% of ProShares Ultra Nasdaq Biotechnology worth $483,000 as of its most recent SEC filing.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Recommended Stories
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
